Table VII.
Interaction | Transporter | Organ | Vss Change | Prediction from Trends | Reference |
---|---|---|---|---|---|
Digoxin+Rifampin | Oatp1a4 uptake | Liver | ↓ 17.9% | ↓ | (68) |
Quinapril+PAH | Oat uptake | Kidney | ↓ 13.7%* | ↔, (↓) | (69) |
Digoxin+Quinidine | P-gp efflux | Liver | ↑ 95.9% | ↓ | (70) |
Tacrolimus+GG918 | P-gp efflux | Liver | ↑ 30.1% | ↓ | (70) |
Talinolol+GG918 | P-gp efflux | Liver | ↑ 74.2% | ↓ | (70) |
Doxorubicin+GG918 | P-gp efflux | Liver | ↑ 70.2%* | ↓ | (71) |
Italicized interactions are those where the data does not match the prediction from the present analysis.
* indicates calculated parameters, not reported in reference
PAH: p-aminohippurate, GG918: GF120918 (Elacridar)